Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project

Archives of General Psychiatry
Madhukar H TrivediSteven P Shon

Abstract

The Texas Medication Algorithm Project is an evaluation of an algorithm-based disease management program for the treatment of the self-declared persistently and seriously mentally ill in the public mental health sector. To present clinical outcomes for patients with major depressive disorder (MDD) during 12-month algorithm-guided treatment (ALGO) compared with treatment as usual (TAU). Effectiveness, intent-to-treat, prospective trial comparing patient outcomes in clinics offering ALGO with matched clinics offering TAU. Four ALGO clinics, 6 TAU clinics, and 4 clinics that offer TAU to patients with MDD but provide ALGO for schizophrenia or bipolar disorder. Patients Male and female outpatients with a clinical diagnosis of MDD (psychotic or nonpsychotic) were divided into ALGO and TAU groups. The ALGO group included patients who required an antidepressant medication change or were starting antidepressant therapy. The TAU group initially met the same criteria, but because medication changes were made less frequently in the TAU group, patients were also recruited if their Brief Psychiatric Rating Scale total score was higher than the median for that clinic's routine quarterly evaluation of each patient. Primary outcomes included (...Continue Reading

Citations

Mar 13, 2014·Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·Elizabeth BannisterMatthew Byerly
Sep 13, 2008·International Journal of Health Care Quality Assurance·Tom C M JoostenIr Bert R Meijboom
Jan 20, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Madhukar H TrivediRichard C Shelton
Jun 24, 2008·Neuropsychiatric Disease and Treatment·Madhukar H TrivediA John Rush
Apr 3, 2009·Journal of Psychiatric Practice·Diane WardenMadhukar H Trivedi
Sep 15, 2009·Primary Care Companion to the Journal of Clinical Psychiatry·Benji T KurianPrabha Sunderajan
Sep 15, 2009·Primary Care Companion to the Journal of Clinical Psychiatry
Nov 13, 2009·European Archives of Psychiatry and Clinical Neuroscience·T WobrockW Gaebel
Sep 22, 2011·Current Psychiatry Reports·David W Morris, Madhukar H Trivedi
May 29, 2013·Current Psychiatry Reports·Daniel M BlumbergerZafiris J Daskalakis
Sep 13, 2006·Vertex : revista argentina de psiquiatriá·Hugo Hirsch
Aug 24, 2006·The Psychiatric Quarterly·Richard M BlochChristina Rausch
Dec 27, 2007·Neuropsychiatric Disease and Treatment·Ira H BernsteinMadhukar H Trivedi
Oct 28, 2005·The New England Journal of Medicine·J John Mann
Mar 24, 2006·The New England Journal of Medicine·Madhukar H TrivediUNKNOWN STAR*D Study Team
Jun 16, 2006·The New England Journal of Medicine·Norman Sussman
Aug 9, 2007·The Pharmacogenomics Journal·A SerrettiJ L Kennedy
Feb 18, 2010·The Journal of Behavioral Health Services & Research·Molly A Lopez, Monica Ramirez Basco
May 4, 2010·Journal of Mental Health·Shibu P ThomasAnand Jayaraman
Jan 1, 2006·International Journal of Psychiatry in Clinical Practice·Min-Soo Lee The Executive Committee For The Korean Medication Algorithm Project For Major Depressive Disorder
Dec 26, 2006·Expert Review of Neurotherapeutics·Hanne Vibe Hansen, Lars Vedel Kessing
Nov 22, 2011·Expert Opinion on Pharmacotherapy·Michele FornaroGiulio Perugi
Aug 2, 2008·Expert Opinion on Pharmacotherapy·Martin LambertChristian G Huber
Nov 29, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·H-J MöllerUNKNOWN European Psychiatric Association
Jul 26, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michele FabrazzoMario Maj
Jan 3, 2012·Cognitive and Behavioral Practice·Stuart EisendrathMaura McLane
Feb 10, 2010·L'Encéphale·S Mouchabac
Jan 26, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Florian SeemüllerHans-Jürgen Möller
Jan 27, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yasushi SatoSunao Kaneko
Sep 17, 2008·Psychosomatics·E Sherwood BrownDavid A Khan
May 27, 2008·Epilepsy & Behavior : E&B·John J BarryUNKNOWN Advisory Group of the Epilepsy Foundation as part of its Mood Disorder
May 22, 2007·Journal of the American Academy of Child and Adolescent Psychiatry·Carroll W HughesUNKNOWN TEXAS CONSENSUS CONFERENCE PANEL ON MEDICATION TREATMENT OF CHILDHOOD MAJOR DEPRESSIVE DISORDER
May 19, 2007·Journal of Affective Disorders·T Michael KashnerRobin B Jarrett
Oct 28, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·James D TewCharles F Reynolds

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.